Homo-MDA

Homo-MDA
Clinical data
Other names	HMDA α-Methyl-γ-(3,4-methylenedioxyphenyl)propylamine; α-Methyl-1,3-benzodioxole-5-propanamine; 3,4-Methylenedioxyphenylaminobutane
Identifiers
	IUPAC name 4-(1,3-benzodioxol-5-yl)butan-2-amine;
CAS Number	40742-32-3;
PubChem CID	162424;
ChemSpider	142612;
ChEMBL	ChEMBL4534949;
CompTox Dashboard (EPA)	DTXSID60961163 ;
ECHA InfoCard	100.359.348
Chemical and physical data
Formula	C11H15NO2
Molar mass	193.246 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CCC1=CC2=C(C=C1)OCO2)N;
	InChI InChI=1S/C11H15NO2/c1-8(12)2-3-9-4-5-10-11(6-9)14-7-13-10/h4-6,8H,2-3,7,12H2,1H3; Key:LWUIKWNECJUNDA-UHFFFAOYSA-N;

Homo-MDA (HMDA), also known as α-methyl-γ-(3,4-methylenedioxyphenyl)propylamine, is a entactogen-like drug related to 3,4-methylenedioxyamphetamine (MDA).^[1] It is an analogue of MDA in which the side chain has been lengthened by one carbon atom.^[1]

Unlike the stimulant amphetamine and the psychedelic DOM, and in contrast to MDA, homo-MDA has no effect on locomotor activity in rodents.^[2] It was found to be more toxic than MDA in rodents.^[3]

The effects of homo-MDA in humans are unknown.^[1] It is not a controlled substance in the United States as of 2011.^[1]

References

^ ^a ^b ^c ^d Shulgin A, Manning T, Daley PF (2011). "#78. Homo-MDA". The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley, CA: Transform Press. pp. 177–179. ISBN 978-0-9630096-3-0. OCLC 709667010.
^ Buxton DA (1972). "Behavioural Actions of Some Substituted Amphetamines". Biochemical and Pharmacological Mechanisms Underlying Behaviour. Progress in Brain Research. Vol. 36. pp. 171–181. doi:10.1016/S0079-6123(08)62519-4. ISBN 978-0-444-40992-8. PMID 4644027.
^ Davis WM, Borne RF (1984). "Pharmacologic investigation of compounds related to 3,4-methylenedioxyamphetamine (MDA)". Substance and Alcohol Actions/Misuse. 5 (2): 105–110. PMID 6147902.